Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Revealing eltrombopag's promotion of human megakaryopoiesis through AKT/ERK-dependent pathway activation.

Haematologica - 1 Dec 2016

Di Buduo Christian A, Currao Manuela, Pecci Alessandro, Kaplan David L, Balduini Carlo L, Balduini Alessandra

Abstract excerpt

Eltrombopag is a small, non-peptide thrombopoietin mimetic that has been approved for increasing platelet count not only in immune thrombocytopenia and Hepatitis C virus-related thrombocytopenia, but also in aplastic anemia. Moreover, this drug is under investigation for increasing platelet counts in myelodysplastic syndromes. Despite current clinical practice, the mechanisms governing eltrombopag's impact on...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzoates
Share to Blood Platelets

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Extracellular Signal-Regulated MAP Kinases

Share to Hydrazines

Share to Megakaryocytes

Share to Pyrazoles

Share to Receptors, Thrombopoietin

Share to Thrombopoiesis

Source

Open in PubMed Open full text

Identifiers

PMID: 27515246
DOI: 10.3324/haematol.2016.146746
PMCID: PMC5479602

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Revealing eltrombopag's promotion of human megakaryopoiesis through AKT/ERK-dependent pathway activation.PMID 27515246Read ↗

Elucidating the Mechanism of Action of the Attributed Immunomodulatory Role of Eltrombopag in Primary Immune Thrombocytopenia: An In Silico ApproachSemantic proximity Read ↗

Insights into Regulatory Factors in Megakaryocyte Development and Function: Basic Mechanisms and Potential TargetsSemantic proximity Read ↗

PI3k/AKT signaling pathway: Erythropoiesis and beyondSemantic proximity Read ↗

A novel nonpeptidyl human c-Mpl activator stimulates human megakaryopoiesis and thrombopoiesis.Semantic proximity Read ↗

Thrombopoietin knock-in augments platelet generation from human embryonic stem cellsSemantic proximity Read ↗

DMAG, a Novel Countermeasure for the Treatment of ThrombocytopeniaSemantic proximity Read ↗

Paclitaxel improves thrombopoiesis in the absence of thrombopoietin receptor (Mpl).Semantic proximity Read ↗

Induced Pluripotent Stem Cell-Derived Megakaryocytes and Platelets for Disease Modeling and Future Clinical Applications.Semantic proximity Read ↗

Establishment and characterization of a new human megakaryoblastic cell line (SET-2) that spontaneously matures to megakaryocytes and produces platelet-like particlesSemantic proximity Read ↗

Eltrombopag for the treatment of the inherited thrombocytopenia deriving from MYH9 mutations.Semantic proximity Read ↗

Successful use of eltrombopag for surgical preparation in a patient with ANKRD26-related thrombocytopenia.Semantic proximity Read ↗

A three-step pathway comprising PLZF/miR-146a/CXCR4 controls megakaryopoiesisSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.